In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Selected Start-Ups (10/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Spun out of London's Imperial College School of Medicine in July, Circassia Ltd. will develop treatments for cat-induced asthma and allergies. Copharos Inc., was formed in August 2000 to develop Vitamin B12-based radioactive imaging and therapeutic agents for the early detection and treatment of breast, lung and other cancers. EyeTech Pharmaceuticals Inc., founded in April 2000, has embarked on Phase IB trials for its drug for wet macular degeneration, a leading cause of adult-onset blindness. Invenux Inc. will use its Evolutionary Chemistry integrated discovery system to identify antibiotic compounds effective against drug-resistant organisms as well as discover drugs with broad-spectrum antibiotic activity. Sensatex/Lifelink Inc. will provide wireless, remote health care monitoring with its Smart Shirt, a special fabric interwoven with sensors that continuously relays information on a patient's vital signs. Sensory Technologies Inc. was formed in November 1999 to commercialize sensory-enhancement research of James Collins, PhD at Boston University's Center for Biodynamics.

You may also be interested in...

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations

Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts